Adams Respiratory Therapeutics Files Lawsuit Against United Research Laboratories/Mutual Pharmaceutical For Infringement Of Mucinex(R) Patent

CHESTER, N.J., Oct. 2 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. today announced that it has filed a lawsuit in the United States District Court for the District of New Jersey against Mutual Pharmaceuticals Co. and United Research Laboratories, Inc. (URL), both wholly owned subsidiaries of Pharmaceutical Holdings Corp. for infringement of U.S. Patent No. 6,372,252, issued in April 2002. The '252 patent, which is listed in the Orange Book with the Food and Drug Administration (FDA) and expires in 2020, relates to Adams' oral solid, extended-release guaifenesin products. Mucinex(R) and its maximum-strength version, marketed under the Humibid(R) brand name, are the only FDA-approved extended-release expectorant products that provide 12-hour relief from chest congestion in one tablet.

The lawsuit is in response to Mutual/URL's notification that it has filed a Paragraph IV Certification in connection with its Abbreviated New Drug Application (ANDA) with the FDA seeking approval to engage in the commercial manufacture, use or sale of guaifenesin extended-release tablets prior to the expiration of the '252 patent.

Adams plans to vigorously defend its exclusive market position for single- entity Mucinex(R) and Humibid(R) products as well as its patent portfolio protecting the Company's oral solid, extended-release guaifenesin products.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

Forward-Looking Statements

This press release contains certain "forward-looking" statements, including the Company's intention to vigorously defend its patent portfolio. Such forward-looking statements can be identified by the words "plan," "believe," "intend," and similar expressions and are subject to risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, the Company's ability to successfully defend its patent position and protect its trade secrets and other proprietary information; and other risk factors set forth under the headings "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Adams' Rule 424(b)(4) Prospectus filed with the SEC on December 9, 2005, and under Item 1A. "Risk Factors" in Adams' Annual Report on Form 10-K for the fiscal year ended June 30, 2006. Except to the extent required by applicable securities laws, Adams is not under any obligation to (and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future events, or otherwise. All statements contained in this press release are made only as of the date of this press release.

Adams Respiratory Therapeutics, Inc.

CONTACT: Investor/Media, Janet M. Barth, +1-908-879-2428, for AdamsRespiratory Therapeutics, Inc.

Back to news